Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
Tumor Immunotherapy01:27

Tumor Immunotherapy

660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Calcium Overloading-Induced UBE2O Upregulation Alleviates Neuronal Apoptosis.

Molecular neurobiology·2026
Same author

ZER1 Restrains Pressure Overload-Induced Cardiac Remodeling by Targeting DVL2 for Gly/N-Degron-Dependent Degradation.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Duration-dependent effects of sucrose intake on fear extinction via distinct mechanisms in the amygdala and hippocampus.

Brain research·2026
Same author

Synthesis of aza-β-lactams <i>via</i> B(C<sub>6</sub>F<sub>5</sub>)<sub>3</sub>-catalyzed Wolff rearrangement/[2 + 2] cascade cyclization of α-diazoketones with diazenes.

Organic & biomolecular chemistry·2026
Same author

Deep Learning for Classifying and Cognitive Profiling of Subcortical Vascular Cognitive Impairment.

Cyborg and bionic systems (Washington, D.C.)·2026
Same author

Multimodal clocks of human aging.

Cell·2026

相关实验视频

Updated: Sep 12, 2025

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
09:33

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

8.0K

改善阿尔茨海默病的免疫疗法

Mengen Xing1, Weihong Song1,2

  • 1Center for Geriatric Medicine, International Center for Alzheimer's Research, Prevention and Treatment, The First Affiliated Hospital and Oujiang Laboratory; Key Laboratory of Alzheimer's Disease of Zhejiang Province, Institute of Aging, Wenzhou Medical University, Wenzhou, Zhejiang, China.

Science (New York, N.Y.)
|August 7, 2025
PubMed
概括

在临床前阿尔茨海默病研究中,一种针对粉样β (Aβ) 的新型修饰抗体显示出更好的安全性和有效性. 这种抗体有望在未来对抗Aβ病理的治疗发展.

科学领域:

  • 神经科学
  • 免疫学
  • 药理学

背景情况:

  • 粉样β斑块是阿尔茨海默病 (AD) 的一个标志.
  • 目前针对Aβ的疗法可能会导致像粉样蛋白相关的成像异常 (ARIA) 这样的不良事件.

研究的目的:

  • 开发和评估一种改性抗体,以提高Aβ向性,并减少副作用.
  • 在AD小鼠模型中评估这种修饰抗体的疗效和安全性.

主要方法:

  • 设计一种具有特定修饰的抗体,以改变其与Aβ的相互作用.
  • 向表现出Aβ病理的转基因小鼠注射修饰的抗体.
  • 评估Aβ斑块负荷,认知功能和不良事件的发生率.

主要成果:

  • 与对照组相比,修改后的抗体显著降低了Aβ斑块负担.
  • 观察到如ARIA等不良事件的显著减少.
  • 认知能力的改善与Aβ病理的减少有关.

结论:

  • 在小鼠模型中,抗体修饰可以增强对Aβ的治疗效果.
  • 这种方法可以提高针对Aβ的AD治疗的安全性.

更多相关视频

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
08:27

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

12.1K
Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

9.4K

相关实验视频

Last Updated: Sep 12, 2025

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
09:33

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

8.0K
Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
08:27

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

12.1K
Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

9.4K